From Wheelchair To Walking! How Amanda L. Beat Stage 3 Cancer at CHIPSA!
Amanda L. was diagnosed with an aggressive bone cancer called chondroblastic osteosarcoma in March of 2017. By the time her doctors discovered it, the disease had metastasized and advanced to stage 3. Amanda was told it was non-curative. But nearly two years after her initial diagnosis, Amanda is still alive to share her story, and remarkably, […]
Continue readingFrom Wheelchair To Walking! How Amanda D. Beat Stage 3 Cancer at CHIPSA!
Amanda Leverett Davis was diagnosed with an aggressive bone cancer called chondroblastic osteosarcoma in March of 2017. By the time her doctors discovered it, the disease had metastasized and advanced to stage 3. Amanda was told it was non-curative. But nearly two years after her initial diagnosis, Amanda is still alive […]
Continue readingNew Video Series Celebrates 22 Late-Stage Cancer Survivors
Last September, 22 people made history as they joined together to celebrate accomplishing the impossible: surviving late-stage cancer. Traveling back to the place where their healing journeys began — CHIPSA Hospital in Tijuana, Mexico — the cancer survivors had the chance to share their stories, meet other patients, and converse with world-renowned doctors, scientists, […]
Continue readingImmunotherapy in 2019: What’s Next for this Cancer Treatment?
2018 saw tremendous improvements in immunotherapy methods that led to positive results for cancer patients all around the United States. 2019 promises even more advancements, and new strategies aim to increase these effective responses. The key to garnering even better immunotherapy results in 2019 will be using combination therapies. Two methods in particular will be front […]
Continue readingNew Immunotherapy Guidelines Will Help Clinicians Treat Lung Cancer
After the FDA approved Opdivo to treat non-small cell lung cancer (NSCLC) in March of 2015, it replaced cytotoxic chemotherapy as the main method of treatment for the disease. Immunotherapy has since become preferable to chemotherapy, as many new checkpoint inhibitors have also been FDA-approved. But because many immunotherapy treatments were introduced to the lab […]
Continue readingOn the Brink of Curing Cancer: How Nobel Prize Winners Offer Hope
The way we understand cancer treatment in the U.S. is changing. This year’s Nobel prizes in medicine honored new scientific breakthroughs that suggest we may be close to finding a cure for cancer. One of the Nobel-prize winners, Dr. James P. Allison, has made great strides in advancing cancer immunotherapy. Immunotherapy is a treatment […]
Continue readingA New Modified Molecule Helps to Tailor Effective Anti-Cancer Response
A mouse study published in Cell Chemical Biology reveals that a new version of the foreign fat molecule alpha-galactosylceramide (a-GalCer) is very successful at inducing inflammatory and anti-tumor responses in humans. The results of this study may be helpful in creating treatments that will prevent the spread of cancer. Past studies have shown that synthetic-GalCer, […]
Continue readingUsing PET Scans to Determine the Efficacy of PD-1 and PD-L1 Targeted Cancer Therapies
Summary According to a recent study that appeared in the March 2018 volume of The Journal of Nuclear Medicine, scientists at Bristol-Meyers Squibb (BMS) are developing a new way for physicians to determine how cancer patients might respond to PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) targeted treatments. Previously, the […]
Continue readingCAR T-Cell Therapy Successfully Treated Mice with Metastatic Colorectal Cancer
CAR T-Cell, or chimeric antigen receptor immunotherapy was recently used in a study to see if it could help prevent the spread of metastatic cancer. In the study humanized CAR T-Cell was successful at killing tumor cells as well as preventing it from spreading. The treatment may be useful for treating other types of […]
Continue readingFirst Patient Receives Phase 1 Clinical Trial Dose of FS118
The clinical trial for an antibody designed to treat advanced cancers has begun with the first dose of FS118. The treatment is supposed to target two immune checkpoint proteins. The study, based in the US, will be enrolling 51 patients who have been diagnosed with metastatic cancers. The patients have not previously responded to […]
Continue reading